Literature DB >> 7002181

A controlled comparison of oxyfedrine, isosorbide dinitrate and placebo in the treatment of patients suffering attacks of angina pectoris.

J Whittington, E B Raftery.   

Abstract

1 In a group of 23 patients with documented ischaemic heart disease who experienced angina pectoris, oral oxyfedrine (24 mg three times daily) was compared with isosorbide dinitrate (10 mg three times daily) and placebo in a double-blind double-crossover clinical trial. 2 Isosorbide dinitrate appeared no better than placebo, either in terms of symptomatic relief or ECG responses to exercise. Thirty eight per cent of patients complained of headaches and 28% had to cease taking the drug for this reason. 3 Oxyfedrine produced statistically significant improvements in both symptom level (P < 0.01) and ECG ST-segment responses to exercise (P < 0.01). The only side effect noted was a reversible loss of taste sensation by one patient. 4 Neither drug produced any adverse changes in any haematological or biochemical parameters. 5 Oxyfedrine is, therefore, to be preferred to isosorbide dinitrate, being both much better tolerated and more efficacious.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002181      PMCID: PMC1430056          DOI: 10.1111/j.1365-2125.1980.tb01746.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise.

Authors:  V Balasubramanian; P K Khanna; G R Naryanan; R S Hoon
Journal:  Postgrad Med J       Date:  1976-03       Impact factor: 2.401

2.  The medical management of angina pectoris.

Authors:  O Paul
Journal:  JAMA       Date:  1977-10-24       Impact factor: 56.272

3.  Oxyfedrine--a partial agonist at -adrenoceptors.

Authors:  P R Beckett; R W Foster
Journal:  Eur J Pharmacol       Date:  1972-11       Impact factor: 4.432

4.  Some comments and reflections on changing interests and new developments in angina pectoris.

Authors:  C K Friedberg
Journal:  Circulation       Date:  1972-12       Impact factor: 29.690

5.  [Stimulation of adrenergic beta-receptors in the heart of normal and reserpinized guinea pigs by oxyfedrine].

Authors:  W R Kukovetz; G Pöch
Journal:  Arzneimittelforschung       Date:  1969-09

Review 6.  Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications.

Authors:  S E Epstein; E Braunwald
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

7.  Effects of ouabain on the left ventricular response to exercise in patients with angina pectoris.

Authors:  D L Glancy; L M Higgs; K P O'Brien; S E Epstein
Journal:  Circulation       Date:  1971-01       Impact factor: 29.690

Review 8.  Beta-adrenergic receptor blocking drugs in angina pectoris.

Authors:  B N Prichard
Journal:  Drugs       Date:  1974       Impact factor: 9.546

9.  Therapy of angina pectoris with propranolol and long-acting nitrates.

Authors:  A N Goldbarg; J F Moran; T K Butterfield; R Nemickas; G A Bermudez
Journal:  Circulation       Date:  1969-12       Impact factor: 29.690

10.  [The effect of ildamen, a cardio-energetic coronary therapeutic agent, on cardiovascular dynamics].

Authors:  N Sternitzke; J A Köhler; E Lang
Journal:  Med Welt       Date:  1966-09-03
View more
  5 in total

1.  Possible mechanisms of action of oxyfedrine as an antianginal drug.

Authors:  J R Parratt; J E Mackenzie
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

Review 2.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

3.  Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study.

Authors:  L Fananapazir; C Bray
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

4.  Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease.

Authors:  J C Kaski; L Araujo; A Maseri
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

5.  Oxyfederine and propranolol--a controlled trial in angina pectoris.

Authors:  J Whittington; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.